HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

Sephora opened 24 stores in the U.S. in 2005 and will "continue to expand vigorously" in established markets as well as high-potential markets such as Central Europe in 2006, LVMH says in annual report released March 2. Profit from recurring operations for Selective Retailing advanced 46% to $417.2 mil. (€1=$1.20) in 2005. In Perfumes and Cosmetics, profit from recurring operations increased 15% to $208 mil., due to major French brands gaining market share and smaller companies maintaining "rapid rate" of growth, according to company. In 2006, Parfums Christian Dior will launch "major skin care and makeup," Guerlain will introduce Orchidée Impériale skin care as well as expand KissKiss, and Parfums Kenzo will launch a new women's scent in the second half, firm notes. Profit from recurring operations for LVMH grew 16% to $3.3 bil...

You may also be interested in...

US Bill Urges Automatic Insulin Interchangeability

A draft Biosimilar Insulin Access Act, intended to waive US interchangeability requirements for FDA-approved biosimilar insulins, has been introduced by representative Glenn Grothman.

Ex-Cipla Executive To Helm JB Chemicals

The former CEO of Cipla’s India business is set to steer JB Chemicals and Pharmaceuticals, as the Indian firm embarks on a new phase of growth, backed by a revamped board, following its takeover by US private equity firm KKR.

Coronavirus Update: Moderna And Pfizer Respond To Vaccine Trial Transparency Demands

Moderna led by releasing the trial protocol for its COVID-19 vaccine study, followed by Pfizer, as industry faces demands for transparency.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts